SmartCeuticals™ Announces The Release Of Its First Product Boscumin™ For The Management Of Joint Inflammation And Pain
SmartCeuticals™ Announces The Release Of Its First Product Boscumin™ For The Management Of Joint Inflammation And Pain
CHICAGO, IL, September 1, 2017 /PRNewswire/ -- SmartCeuticals™, Inc, a physician-founded company that develops all-natural pharmaceutical-grade, clinically validated formulas announces the launch of its first product. Boscumin™, a patent-pending turmeric and boswellia complex, is designed to provide unparalleled joint and inflammation support and relief to individuals suffering from acute, chronic, and joint related conditions including: osteoarthritis, rheumatoid arthritis, psoriatic arthritis, bursitis, tendonitis, fibromyalgia, sciatica, and other conditions of inflammation
"It needs to be effective and it must be safe, period”, stated Sreek Cherukuri, M.D., CEO and Chief Medical Officer for the company. “Those are the principles we stand on as a company and as such, the ingredients in Boscumin have been validated in over 30 human clinical studies, following strict FDA drug protocols. The results were more than encouraging. For the joint and inflammation indication alone, we found a 29x increase in bioavailability over standard purified curcumin, a nearly 1000x increase over raw turmeric alone, and more importantly, a 300+% increase in comfort and mobility among study participants compared to placebo.”
The majority of joint discomfort is the result of inflammation from injury or degradation of ligaments, tendons, or the bone that make up a joint. Boswellic acids and curcumin, derived from boswellia and turmeric respectively, are powerful natural anti-inflammatories which have long been used in Ayurvedic (East Indian) medicine. However, both of those substances, are poorly absorbed into the human body. 1 gram of raw turmeric, for instance, provides no detectable levels of curcumin in the body. This concept of absorption is commonly referred to as bioavailability and both boswellic acid and curcumin have very low bioavailability.
“That is where the innovation in Boscumin comes in,” says Dr. Cherukuri, “We’ve designed Boscumin to drastically increase boswellic acid and curcumin bioavailability and deliver more of those healing agents to the joints in the body where they can do really provide benefit.” Cherukuri went on to add, “We feel that Boscumin provides the first effective natural alternative to the use of NSAIDS, Tylenol®, and especially to opioids, which have been a plague on society for the last decade. This is a very exciting time for us, we’ve proven the efficacy in clinical trials and now we want to get those benefits out to people who really need them”
According to the company, Boscumin becomes available today via the company’s website at www.boscumin.com.
About SmartCeuticals:
Founded by award-winning surgeon and consumer health advocate, Sreek Cherukuri MD, SmartCeuticals is built on the principles of science, quality, clinical efficacy, and transparency. SmartCeuticals fuses nature with science to find safe, natural, and effective paths to achieving, maintaining, and advancing human wellness. The innovations and therapies are developed based on rigorous scientific research, undergo comprehensive clinical validation (following FDA drug trial protocols), and are produced using strict pharmaceutical production standards. Finally, since the FDA does not regulate dietary supplements before they come to market and since label fraud is rampant in the industry, SmartCeuticals has set the bar for transparency, providing the customer with 3rd party verification testing to prove every bottle has both the highest quality and purity available on the market. For more information please visit www.boscumin.com or email media@smartceuticals.com.
